Access Route
Access-route map (public, private and provincial exceptions), launch timeline, top 10 risks
Typical fit: Deciding whether and when to launch
For emerging biopharma and international sponsors
Know your Canadian access route before launch decisions lock in.
The Canada Access & Launch Readiness Assessment gives commercial and market-access leaders a clear view of payer routes, partner options, patient-support requirements and launch dependencies in 4–6 weeks. It’s designed for teams launching in Canada within about 18 months, including sponsors without a Canadian affiliate.
The access problem
Approval is the start of Canadian access, not the end.
Health Canada approval (NOC)
Public drug plans
CDA-AMC reviewpCPA negotiationProvincial listing
≈ 906 daysaverage from Health Canada approval to first public listing, 2018–2023¹
Private payers
Insurer submissionsPrior authorizationCoverage under private plans
Patient support programs
EnrolmentReimbursement navigationBridging support
Can start earlier, depending on product and payer
¹ PMPRB, Factors delaying the public listing of drugs in Canada (2025) · Quebec follows a separate INESSS review and RAMQ listing path.
Getting the route right early shapes which partners you sign, what you budget and how you sequence your launch.
¹ PMPRB, 2025 · ² Health Canada · ³ CMAJ, 2023
Fit
A good fit if:
- A Health Canada submission, approval or launch decision is within about 18 months.
- Your Canadian team is small, new or not yet in place.
- Your route through public plans, private payers, channels or support-program partners isn’t settled.
- You need a decision-ready plan before committing to a permanent team or a large vendor contract.
Probably not a fit if you need regulatory submissions prepared or a full-service patient-support operator. We can help you scope and select those partners.
Three scope levels
Canada Access & Launch Readiness Assessment
Fixed scope, 4–6 weeks, led by Malay Panchal with contract market-access specialists as needed.
Recommended
Launch Plan
Access Route, plus patient-support program specification and budget range, private-payer strategy, vendor shortlist and draft RFP
Typical fit: Launch in 12–18 months, vendors not yet chosen
Launch-Ready
Launch Plan, plus a PAAB-aware messaging plan, a 90-day implementation plan and two stakeholder workshops
Typical fit: Launch inside 12 months, team needs alignment
The fee is fixed and agreed in a written proposal. Final deliverables depend on your product, timing and the information available.
How an engagement runs
Defined scope. Decision-ready outputs.
Align
Identify the decision owner, desired outcome, boundaries and evidence needed.
Assess
Review relevant processes, opportunities and constraints with the appropriate stakeholders.
Recommend
Deliver a practical business case, prioritized options, accountabilities and an action roadmap.
Execute (if agreed)
Support implementation or fractional leadership under a separate written scope.
Product X (hypothetical)
- Phase 1Decision owner, scope and success measures agreed
- Phase 2Segments, channels and partner options assessed
- Phase 3Business case, prioritized options and accountabilities
- Phase 4Sequenced launch roadmap and open questions for specialists
Illustrative structure only. Not a client project; actual scope and timing are set in a written proposal.
Other services
Already launched, or need something narrower?
Program & Vendor Performance
For established brand and patient-services teams. Review support-program scope, vendor responsibilities, reporting, pharmacy-channel execution and commercial handoffs. Outcome: a prioritized operating improvement plan.
Explore →Fractional Commercial & Launch Leadership
Accountable Canadian commercial or launch leadership for biopharma around agreed priorities while a permanent team takes shape. Each mandate sets out hours, accountabilities, reporting and conflict checks, with any specialist costs agreed separately.
Outcome: Named priorities, owners and monthly measures.
Discuss a Mandate →Clinical Trial Medication Readiness: Advisory
For study sponsors and clinical supply teams with defined studies. Advisory on medication readiness and pharmacy-model questions. We don’t run dispensing or pharmacy-card programs. Outcome: a scoped readiness and gap assessment.
Discuss a Study →Common questions
Typical business questions we help resolve.
- What needs to be true before we commit to a Canadian launch?
- Which commercial partners and channels deserve priority?
- Where are our program costs, handoffs or vendor responsibilities unclear?
- Do we have the capacity to execute our plan without adding permanent leadership?
- What Canadian medication and pharmacy-model questions must a study sponsor resolve?
Leadership
Launch experience, plus a pharmacy view most advisers lack.
Malay Panchal, MBA, RPh, is a former life sciences CEO and chief revenue officer. He has launched more than 50 product lines internationally, including 6 in Canada and the U.S. with over $10 million in contracted sales, and has managed $15M+ in clinical-trial funds across 25 Canadian trials. Twenty years of running pharmacies and clinics mean he knows where coverage, paperwork and dispensing slow patients down. Specialists and delivery partners join as the scope requires.
Scope
What we do — and what we coordinate.
Our core work is commercial and operational advisory. We work alongside your patient-support provider, distributor and specialty pharmacy partners rather than replacing them. We do not act as a dispensing pharmacy, clinical trial sponsor, importer or regulatory agency. Where an assignment requires specialist regulatory, clinical, legal, reimbursement or licensed pharmacy work, roles and qualified providers are agreed separately.
Questions
Frequently asked questions
How long does the assessment take, and how is it priced?
Four to six weeks, for a fixed fee agreed in a written proposal before work starts.
Do you replace our patient-support provider or market-access consultancy?
No. We help you decide what you need, then choose and manage the right partners. Where an established provider or specialist is the better fit, we’ll say so.
Do you prepare regulatory submissions?
We focus on commercial and operational advisory. Regulatory submissions require an appropriately qualified specialist and separately agreed scope.
Can you support companies entering Canada?
Yes. We can assess commercial priorities, channels, partners and launch-readiness questions, with specialist regulatory or access components scoped separately.
Can you run a clinical trial pharmacy card program?
We do not currently market an active dispensing or pharmacy-card operating platform. We can evaluate defined advisory needs relating to medication readiness and program structure, subject to scope and suitability.
Do you implement or only advise?
Implementation support and fractional leadership are available where agreed in a separate scope with appropriate resources.
What is a good starting engagement?
A clearly defined business decision, executive sponsor and access to the relevant non-patient operational information.
Discuss a Canadian launch
Tell us about your Canadian launch.
Share your product’s stage, timing and current Canadian team. We’ll reply with whether the assessment fits and a proposed scope.